AFT Pharmaceuticals - Recovery driven by strong H222
AFT Pharmaceuticals (AFT) reported FY22 revenue of NZ$130.3m, up from NZ$113.1m in FY21, driven by improved performance in H222 (versus H122) amid...
694 Views
AFT Pharmaceuticals: 1H22 Result — A Bump in the Road
AFT Pharmaceuticals1H22 Result — A Bump in the Road RESEARCH INSIGHTS AFT Pharmaceuticals (AFT) reported a lower than expected underlying 1H22...
859 Views
AFT Pharmaceuticals (AFT): 1H22 Result – Initial Impressions
AFT Pharmaceuticals (AFT)1H22 Result – Initial Impressions AFT Pharmaceuticals (AFT) reported a 1H22 result below expectations, but significantly...
885 Views
AFT Pharmaceuticals - 14% revenue growth despite COVID-19 headwinds
AFT Pharmaceuticals recently reported its results for H122. Operating revenue grew strongly by 14% year-on-year to NZ$55.5m, despite the impact of...
786 Views
Company Coverage: Temporary Analyst Change
Company Coverage Temporary Analyst Change We temporarily transfer coverage of the following companies to Matt Montgomerie due to...
369 Views